These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 25035388

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.
    Robson J.
    Heart; 2008 Oct; 94(10):1331-2. PubMed ID: 18701534
    [No Abstract] [Full Text] [Related]

  • 3. Statins in the elderly: what evidence of their benefit in prevention?
    Steg PG, Tissot CM.
    Arch Cardiovasc Dis; 2010 Feb; 103(2):61-5. PubMed ID: 20226424
    [No Abstract] [Full Text] [Related]

  • 4. Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease.
    Lardizabal JA, Deedwania P.
    Cardiol Clin; 2011 Feb; 29(1):87-103. PubMed ID: 21257102
    [Abstract] [Full Text] [Related]

  • 5. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.
    Jialal I, Smith G.
    Metab Syndr Relat Disord; 2012 Jun; 10(3):159-60. PubMed ID: 22568574
    [No Abstract] [Full Text] [Related]

  • 6. [Update: clinical lipidology].
    Parhofer KG.
    MMW Fortschr Med; 2013 Jul 25; 155(13):49-52; quiz 53-4. PubMed ID: 23964509
    [No Abstract] [Full Text] [Related]

  • 7. [Part II. Combination statin plus fibrate regimens (free and fixed)].
    Clin Investig Arterioscler; 2016 Jul 25; 28 Suppl 3():11-9. PubMed ID: 27473466
    [No Abstract] [Full Text] [Related]

  • 8. Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance.
    Cooper A, O'Flynn N, Guideline Development Group.
    BMJ; 2008 May 31; 336(7655):1246-8. PubMed ID: 18511800
    [No Abstract] [Full Text] [Related]

  • 9. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult.
    Anderson TJ, Grégoire J, Pearson GJ, Barry AR, Couture P, Dawes M, Francis GA, Genest J, Grover S, Gupta M, Hegele RA, Lau DC, Leiter LA, Lonn E, Mancini GB, McPherson R, Ngui D, Poirier P, Sievenpiper JL, Stone JA, Thanassoulis G, Ward R.
    Can J Cardiol; 2016 Nov 31; 32(11):1263-1282. PubMed ID: 27712954
    [Abstract] [Full Text] [Related]

  • 10. Statins: have we found the Holy Grail?
    Jeger R, Dieterle T.
    Swiss Med Wkly; 2012 Nov 31; 142():w13515. PubMed ID: 22315166
    [Abstract] [Full Text] [Related]

  • 11. Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.
    Mathew RO, Rosenson RS, Lyubarova R, Chaudhry R, Costa SP, Bangalore S, Sidhu MS.
    Cardiovasc Drugs Ther; 2021 Jun 31; 35(3):479-489. PubMed ID: 32556851
    [Abstract] [Full Text] [Related]

  • 12. Management of hyperlipidemia in older adults.
    Alexander KP, Blazing MA, Rosenson RS, Hazard E, Aronow WS, Smith SC, Ohman EM.
    J Cardiovasc Pharmacol Ther; 2009 Mar 31; 14(1):49-58. PubMed ID: 19124599
    [Abstract] [Full Text] [Related]

  • 13. Recommendations of the second Indo-U.S. health summit on prevention and control of cardiovascular disease among Asian Indians.
    Enas EA, Singh V, Munjal YP, Gupta R, Patel KC, Bhandari S, Agarwal AK, Joshi SR, Anoop M, Prabhakaran D, Shah B, Reddy S, Sharma B, Trehan N, Yavagal ST, Kasliwal RR, Second Indo-US Health Summit Expert Panel.
    Indian Heart J; 2009 Mar 31; 61(3):265-74. PubMed ID: 20503833
    [No Abstract] [Full Text] [Related]

  • 14. Commentary: Controversies in NICE guidance on lipid modification for the prevention of cardiovascular disease.
    Cappuccio FP.
    BMJ; 2008 May 31; 336(7655):1248-9. PubMed ID: 18511801
    [No Abstract] [Full Text] [Related]

  • 15. [Clinical practice guidelines for the management of dyslipidemia in chronic kidney disease].
    Shoji T.
    Nihon Jinzo Gakkai Shi; 2013 May 31; 55(7):1267-75. PubMed ID: 24288962
    [No Abstract] [Full Text] [Related]

  • 16. [Multimodal therapy of dyslipidemia].
    Stahn A, Hanefeld M.
    Clin Res Cardiol Suppl; 2011 May 31; 6():10-6. PubMed ID: 22528173
    [Abstract] [Full Text] [Related]

  • 17. Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration.
    Brea A, Millán J, Ascaso JF, Blasco M, Díaz A, Hernández-Mijares A, Mantilla T, Pedro-Botet JC, Pintó X.
    Clin Investig Arterioscler; 2018 May 31; 30(4):188-192. PubMed ID: 29789212
    [Abstract] [Full Text] [Related]

  • 18. The effect of fibrate-statin combination therapy on cardiovascular events: a retrospective cohort analysis.
    Wierzbicki AS, Morrell J, Hemsley D, McMahon Z, Crook MA, Wray R.
    Curr Med Res Opin; 2010 Sep 31; 26(9):2141-6. PubMed ID: 20662558
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations.
    Hamilton-Craig I, Kostner KM, Woodhouse S, Colquhoun D.
    Int J Evid Based Healthc; 2012 Sep 31; 10(3):181-90. PubMed ID: 22925614
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.